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Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the human
cortex. The food supplement version of GABA is widely available online. Although many
consumers claim that they experience benefits from the use of these products, it is
unclear whether these supplements confer benefits beyond a placebo effect. Currently,
the mechanism of action behind these products is unknown. It has long been thought
that GABA is unable to cross the blood–brain barrier (BBB), but the studies that have
assessed this issue are often contradictory and range widely in their employed methods.
Accordingly, future research needs to establish the effects of oral GABA administration on
GABA levels in the human brain, for example using magnetic resonance spectroscopy.
There is some evidence in favor of a calming effect of GABA food supplements, but
most of this evidence was reported by researchers with a potential conflict of interest.
We suggest that any veridical effects of GABA food supplements on brain and cognition
might be exerted through BBB passage or, more indirectly, via an effect on the enteric
nervous system. We conclude that the mechanism of action of GABA food supplements
is far from clear, and that further work is needed to establish the behavioral effects of
GABA.
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Introduction
Gamma-aminobutyric acid (GABA) serves as the main inhibitory neurotransmitter in the human
cortex (Roberts and Kuriyama, 1968; Petroff, 2002). In recent years it has become widely available
as a food supplement. In Europe and the United States, GABA is considered a “food constituent”
and a “dietary supplement,” respectively. As such, manufacturers are not required to provide
evidence supporting the efficacy of their products as long as they make no claims with regards
to potential benefits in relation to specific diseases or conditions. These GABA food supplements
can be purchased online via numerous websites, including web shop giants such as Amazon.com,
with often very positive customer reviews. Hundreds of people report that these supplements
have helped them alleviate anxiety and/or improve sleep quality, in addition to other beneficial
effects. Interestingly, GABA has long been thought to be unable to cross the blood–brain
barrier (BBB), which raises questions about the mechanisms of action behind such beneficial
effects (Roberts et al., 1958; Van Gelder and Elliott, 1958; Kuriyama and Sze, 1971; Knudsen
et al., 1988). Through what mechanisms do these products exert their action? Do they rely on
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FIGURE 1 | The difference between capillaries as they are generally found in the body versus the ones in the brain and the possible ways for a
substance to move across these capillaries.
a placebo effect only? Do they exert an effect through peripheral
effects outside of the brain?Or is GABA able to cross the BBB after
all?
The current paper aims to give a succinct overview of recent
understanding of GABA’s BBB permeability (Blood–Brain Barrier
Permeability), the role of GABA in treatment of diseases (GABA,
Diseases, and Treatment), its role as a food supplement (GABA as
a Food Supplement), and the possibility that this food supplement
might affect the central nervous system through an effect on
the enteric nervous system (Enteric Nervous System Effects of
GABA).
Blood–Brain Barrier Permeability
The BBB protects most of the brain from toxins and ion
abnormalities that find their way into vascular space through
ingestion, infection, or other means (Purves et al., 2004). On
the one hand, the BBB is important in keeping the brain safe
from harmful substances. On the other hand it severely limits the
passage of substances into the brain that might be beneficial to the
individual, such as drugs to treat central nervous system disorders
(Pardridge, 2005).
The BBB is made up by neighboring capillary endothelial
cells. These cells are connected via tight junctions, which are
impermeable (Brightman and Reese, 1969). As a consequence,
molecules need to enter via active uptake by specialized
transporter molecules or diffusion into the cells of the BBB
(Pardridge, 2005, 2007). Tight junctions are responsible for the
brain’s high resistance to outside materials. These tight junctions
are not present in the rest of the body, where much more
ionic and molecular traffic is possible (see Figure 1; Purves
et al., 2004). As a consequence, the diffusion of a substance
depends on its ability to cross the cell membrane, which
consists largely of a lipid bilayer. The ability of a substance to
pass through this lipid bilayer (i.e., its lipophilicity) depends
largely on basic chemical properties (Lipinski, 2000; Pardridge,
2005).
FIGURE 2 | GABA’s chemical structure.
Initial studies from the fifties reported GABA’s inability
to cross the BBB (Van Gelder and Elliott, 1958). Since then,
several research groups have replicated this finding (Roberts
et al., 1958; Kuriyama and Sze, 1971; Knudsen et al., 1988).
However, a number of studies have reported that GABA does
cross the BBB, albeit in small amounts (Frey and Löscher,
1980; Löscher, 1981; Löscher and Frey, 1982; Al-Sarraf,
2002; Shyamaladevi et al., 2002). This discrepancy could be
the result of variation in chemical compounds, method of
administration (i.e., oral versus injection), and the species
used.
With regards to the first factor, not every study has employed
the same chemical compound. One study administered 4-amino-
3-hydroxybutyric acid (Kuriyama and Sze, 1971). Although this
compound has a different chemical structure than GABA (i.e., an
extra OH group), this study is often cited as providing evidence
for GABA’s inability to cross the BBB. In view of the role that
simple chemical properties play in BBB permeation, it might
be problematic to generalize findings with different chemical
compounds to GABA as it is found in the central nervous system
and its food supplement version. All other studies that have
reported evidence for or against GABA’s BBB permeability either
administered radioactively labeled GABA (which is chemically
identical to GABA, see Figure 2), or did not further specify the
kind of GABA they used.
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A second factor that may, in principle, account for the
discrepancy between animal studies concerns the significant
variation in methods of GABA administration. GABA was
administered either by intraperitoneal injection (Van Gelder and
Elliott, 1958; Kuriyama and Sze, 1971; Frey and Löscher, 1980;
Löscher, 1981; Shyamaladevi et al., 2002), intravenous injection
(Roberts et al., 1958; Löscher andFrey, 1982;Knudsen et al., 1988),
or the bilateral in situ brain perfusion technique (Al-Sarraf, 2002).
However, there appears to be no systematic relationship between
the method of administration and the research outcome; positive
and negative evidence has been found with all of these methods.
Thirdly, the reported studies differ in the species of animals
tested. Most studies used rats (Van Gelder and Elliott, 1958;
Kuriyama and Sze, 1971; Al-Sarraf, 2002; Shyamaladevi et al.,
2002), but mice (Roberts et al., 1958; Frey and Löscher, 1980),
rabbits (Van Gelder and Elliott, 1958; Kuriyama and Sze, 1971),
and dogs (Löscher and Frey, 1982) have also been used. As with
the employedmethodologies, both positive and negative evidence
has been found with these different species.
One limitation of this field is that there have been no studies
with humans that directly assessed GABA’s BBB permeability.
This is not so surprising given the limited number of methods
for measuring GABA levels in the human brain. GABA levels
have been determined in post-mortem tissue samples (Perry
et al., 1973). Additionally, neocortical slices have been extracted
from epileptic patients undergoing surgery (Errante et al., 2002),
but these methods have not been employed to assess the
effect of GABA administration on brain GABA levels. The
obvious noninvasive candidate for such an assessment is magnetic
resonance spectroscopy (MRS), but we are not aware of any MRS
studies that assessed brain GABA levels after administration of
GABA. Assessment of GABA concentrations in the brain using
MRS requires a careful experimental design, since GABA is not
only present in the brain, but also in blood vessels located outside
of the BBB. Tissue fraction analyses estimating blood, CSF, gray
matter and white matter presence within each volume of interest
should therefore be incorporated (Draper et al., 2014).
Interestingly, evidence has been found for the presence of
a GABA-transporter in the BBB (Takanaga et al., 2001). The
expression of such a transporter indicates that GABA can enter
and/or exit the brain through facilitated transport. In mice, the
brain efflux rate for GABA was found to be 17 times higher
than the influx rate (Kakee et al., 2001). This complicates the
interpretation of GABA concentrations in the brain, and it is
possible that this may have led to an underestimation of the extent
to which GABA is able to cross the BBB. That is, some studies may
have found little evidence for GABA’s BBB permeability because
of the high efflux rate.
GABA, Diseases, and Treatment
Increasing GABA in the brain has for years been the focus of drug
development aiming to alleviate the severity of epileptic seizures
(Hawkins and Sarett, 1957; Wood et al., 1979; Gale, 1989; Petroff
et al., 1995). Initial studies examined the efficacy of administering
GABA directly. One study reported a reduction in the amount
of seizures in epileptic patients who were administered a very
high dose of GABA (0.8 g/kg daily; Tower, 1960). However,
this result was found only in four out of twelve patients.
Additionally, the patients in whom the administration of GABA
did have an effect were children below the age of 15. This
finding is in line with the suggestion that the BBB permeability
to GABA decreases with age (Al-Sarraf, 2002). Perhaps more
importantly, GABA’s half-life is about 17 min in mice (Kakee
et al., 2001). If the half-life has a similar short duration in humans,
direct administration of GABA is unsuitable as pharmacological
treatment of epilepsy.
The GABA analog gabapentin was developed as an anti-
epileptic drug. Gabapentin functions by modulating enzymes
involved in GABA synthesis. It differs in chemical structure
from GABA and its half-life is much longer (McLean, 1994).
One MRS study in humans has found that the administration
of gabapentin increased brain GABA levels by 55.7% (Cai et al.,
2012). Nonetheless, a study exploring the effects of gabapentin in
both rat and human neocortical slice preparations suggests that
there might be a considerable difference between rodents and
humans in the effects on GABA levels: gabapentin was found
to increase GABA concentrations by 13% in human neocortical
slices, while having no significant effect in rat neocortical slices
(Errante et al., 2002).
Patients with Huntington’s disease also have reduced GABA
levels in the brain (Perry et al., 1973), but administration of
GABA to remedy this deficiency has shown mixed results with
regards to the reduction of symptoms (Barbeau, 1973; Fisher et al.,
1974; Shoulson et al., 1976). Of course, that the administration of
GABA does not consistently alter the symptoms in complex and
multifaceted disorders such as epilepsy and Huntington’s disease,
does not necessarily mean that GABA is unable to affect the brain.
GABA as a Food Supplement
In recent years researchers have reported a number of placebo-
controlled studies in which GABA was administered as a food
supplement to healthy participants and participants with a history
of acrophobia. One study found an increase in alpha waves in
healthy participants and reduced levels of immunoglobulin A
(IgA; an indicator of immune system functioning) in participants
with a history of acrophobia when they were exposed to
heights (Abdou et al., 2006). However, the sample size for the
second finding was very small (four participants per group).
Another study reported reduced heart rate variability and salivary
chromogranin A (CgA) during an arithmetic task compared
to a control group after the administration of GABA-enriched
chocolate (Nakamura et al., 2009). A third study reported
less salivary cortisol and CgA than a control group during
a psychological stress-inducing arithmetic task. Additionally,
participants who received 50 mg of GABA dissolved in a beverage
reported less psychological fatigue after completion of the task
(Kanehira et al., 2011). Finally, in a fourth study, participants
were found to show a decrease in alpha waves over time while
performing an arithmetic task. This decrease was smaller in the
group that orally received GABA (100 mg) compared to a control
group (Yoto et al., 2012). By way of comparison, one would
have to eat 2.34 kg of uncooked spinach in order to consume a
similar amount of GABA, and spinach is relatively rich in GABA
compared to other foods (Oh et al., 2003).
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The results of these studies support the claims made by
hundreds of consumers of GABA food supplement products
and fit with a growing trend in which GABA is administered
through everyday (natural) foods (Diana et al., 2014). However,
there are some caveats to consider. First, at least one of the
authors in each of these four studies was affiliated with the
company that produces the GABA supplement in question.
However, a declaration of conflicting interests is lacking in
three out of four of these studies. Second, the reported studies
used “pharma-GABA,” which is produced for the Asian market
through a fermentation process using a strain of lactic acid
bacteria, Lactobacillus hilgardii K-3 (Kanehira et al., 2011).
Pharma-GABA has been approved by the FDA as a food
ingredient (Food and Drug Administration, 2008). While the
manufacturer of pharma-GABA suggests that there are important
differences with the synthetic GABA supplement sold online in
Western countries (http://www.natural-pharmagaba.com/q-and-
a.html), these differences refer to the production process and
the occurrence of potentially harmful byproducts in synthetically
produced GABA, and not to the chemical structure of the active
compound GABA.
A recent study by Steenbergen et al. (2015a) with human
subjects has shown that the ingestion of synthetic GABA (800mg)
enhanced the ability of prioritized planned actions and inhibitory
control (as indexed by the stop-change task; Verbruggen and
Logan, 2008; Steenbergen et al., 2015a). However, in view of
the lack of evidence with regards to GABA’s BBB permeability
in humans, the mechanism through which GABA might have
exerted these effects remains unclear. The same holds for the
pharma-GABA studies that were discussed above: none of these
effects exclude an indirect of GABA on the brain. The oral intake
of these supplements may have exerted these effects through
indirect pathways, for example through the enteric nervous
system (ENS).
Enteric Nervous System Effects of GABA
The bidirectional signaling between the brain and the ENS is vital
in maintaining homeostasis (Cryan and O’Mahony, 2011). Even
though most research thus far has focused on the signaling from
the brain to the gut, an increasing number of studies has explored
the influence of the gut’smicrobiota on the brain. For example, gut
microbiota have been shown to improvemood and reduce anxiety
in patients with chronic fatigue (Logan and Katzman, 2005; Rao
et al., 2009). Similarly, oral intake of probiotics resulted in reduced
urinary cortisol and perceived psychological stress (Messaoudi
et al., 2011) and reduced reactivity to sadmood (Steenbergen et al.,
2015b) in healthy subjects.
It has been found that certain probiotic strains are able to
produce GABA in vivo. Specifically, bacteria from the strains
Lactobacillus and Bifidobacterium were effective at increasing
GABA concentrations in the ENS (Barrett et al., 2012). Indeed,
both GABA and its receptors are widely distributed through
the ENS (Auteri et al., 2015). Additionally, there is considerable
communication between the gut and the brain through the
vagal nerve (Cryan and O’Mahony, 2011; Cryan and Dinan,
2012). This nerve consists, for the most part, of sensory
nerve fibers that relay information about the state of bodily
organs to the central nervous system (Thayer and Sternberg,
2009).
A study inmice showed that the administration of Lactobacillus
rhamnosus (JB-1) consistently modulated the mRNA expression
of GABAAa2, GABAAa1, and GABAB1b receptor subunits (Bravo
et al., 2011), receptors commonly associated with anxiety-like
behavior. Indeed, on a behavioral level the L. rhamnosus (JB-
1)-fed mice were less anxious and displayed antidepressant-
like behaviors in comparison with controls. Furthermore, the
administration of these bacteria reduced the stress-induced
elevation of corticosterone compared to the control mice.
Importantly, none of these effects were present in mice that
underwent vagotomy (Bravo et al., 2011).
In humans, the stimulation of the vagus nerve through
transcutaneous vagus nerve stimulation (tVNS) has been used to
treat refractory epilepsy (Vonck et al., 2014). This technique has
been shown to affect norepinephrine, acetylcholine and GABA
concentrations (Van Leusden et al., 2015). With regards to GABA,
VNS seems to increase the level of free GABA in the cerebrospinal
fluid (Ben-Menachem et al., 1995). Similarly to the administration
of synthetic GABA (Steenbergen et al., 2015a), active tVNS was
found to enhance the ability of prioritizing and cascading different
actions when performing a stop-change paradigm (Steenbergen
et al., 2015c).
To summarize, bacteria from the Lactobacillus spp. strain
contribute to the formation of GABA in the ENS. The oral
administration of bacteria from this strain can influence
GABAergic firing in the mice brain through the vagus nerve.
Furthermore, stimulation of the vagal nerve through tVNS has
been shown to affect processes thought to be GABAergic in
humans. Finally, a similar behavioral effect has been found both
for the administration of synthetic GABA and tVNS with regards
to action cascading. Even if GABA is unable to cross the BBB
at all in humans, an indirect effect through the ENS might be a
viable route for an effect of GABA food supplements. The link
between the oral administration of GABA, the vagal nerve and
GABA levels in the brain has not been established yet, but in view
of the available evidence it is a promising candidate for future
research.
Conclusion
In this paper we have discussed the conflicting evidence with
regards to GABA’s BBB permeability. There are both a number of
studies that were unable to show that GABA crosses the BBB and
a number of studies that did show GABA’s ability to cross. In view
of the multitude of employed methods and species, in addition to
the finding that GABA metabolism might differ between rodents
and humans (Errante et al., 2002), it is not possible at this time
to come to a definite conclusion with regards to GABA’s BBB
permeability in humans. The mixed findings concerning GABA
administration in clinical populations suffering from epilepsy or
Huntington’s disease are insufficient to rule out a possible effect of
GABA in the brain. Perhaps the amount of GABA that reaches the
brain is too small to be of clinical significance, but large enough for
an effect in a stop-change paradigm. We believe that MRS studies
are the most promising technique to directly assess the effect
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of GABA administration on GABA levels in the human brain.
Interestingly, in one of the discussed studies with rats, GABA by
itself was found to increase brain GABA by 33%, but when GABA
was administered togetherwith L-arginine, brainGABA increased
by 383.3% (Shyamaladevi et al., 2002). The authors suggest that
this dramatic increase in brain GABA might be caused by an
L-arginine-mediated increase in nitric oxide, which is thought
to affect BBB permeability (Shukla et al., 1996). It would be
interesting to see if this effect can be replicated in humans.
Furthermore, we discussed GABA’s role as a food supplement
and the way in which these products might exert an effect other
than through BBB permeation. There is some evidence for the
claims made by hundreds of consumers online concerning the
calming effects of GABA food supplements, but evidence from
independent studies is needed. In addition, even if a calming effect
of GABA can be reliably demonstrated, the mechanism through
which these supplements work is unclear. We have suggested
that GABA supplements might work through the ENS, but far
more research is needed in order to support this hypothesis.
Indeed, at this point it is even too early to conclude whether these
supplements reach the brain in sufficient concentrations to exert
a biologically relevant effect.
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